Ventoxen 10 mg Tablet

Generic Name: Venetoclax
Brand Name: Ventoxen
Strength: 10 mg
Form: Oral Tablet
Pack Size: Often part of a starter pack or dose ramp-up pack
Manufacturer: Everest Pharmaceuticals
Distributed by: NP Molecule

Indications:

Ventoxen (Venetoclax) is indicated for the treatment of:

• Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion

• Acute myeloid leukemia (AML) in combination with azacitidine, decitabine, or low-dose cytarabine, especially in newly diagnosed elderly or unfit patients

Pharmacology:

Venetoclax is a BCL-2 inhibitor.
BCL-2 is a protein that helps cancer cells survive by preventing programmed cell death (apoptosis).
By inhibiting BCL-2, Ventoxen promotes apoptosis in cancerous blood cells, making it highly effective in hematologic malignancies.

Dosage & Administration:

• Ventoxen is initiated using a dose ramp-up schedule to reduce the risk of tumor lysis syndrome (TLS).
  Example:

  • Day 1: 20 mg

  • Day 2: 50 mg

  • Day 3: 100 mg

  • Day 4: 200 mg

  • Day 5: 400 mg

• The 10 mg tablet is commonly used at the beginning of the treatment cycle and in dose adjustments.

Always taken with food and water, and under physician guidance.

Drug Interactions:

• Strong CYP3A inhibitors (e.g., ketoconazole) can significantly increase Venetoclax levels — may require dose adjustments.

• Avoid grapefruit and Seville oranges.

Contraindications:

• Known hypersensitivity to Venetoclax

• Concomitant use with strong CYP3A inhibitors at initiation

Side Effects:

• Common: Neutropenia, diarrhea, nausea, fatigue, anemia

• Serious: Tumor lysis syndrome, infections, febrile neutropenia

Pregnancy & Lactation:

• Not recommended during pregnancy; may cause fetal harm

• Avoid breastfeeding during and for 1 week after the last dose

Precautions & Warnings:

• Monitor for tumor lysis syndrome (TLS) – requires hydration and prophylaxis

• Frequent CBC and chemistry panel monitoring during dose escalation

• May require hospitalization during initial dosing for high-risk patients

Overdose Effects:

• Potential for profound neutropenia and tumor lysis

• Provide immediate supportive care

Therapeutic Class:

• BCL-2 Inhibitor / Targeted Oral Therapy

Storage Conditions:

• Store below 30°C

• Protect from moisture and light

• Keep out of reach of children